Payment overview · 2025
General Payments
$1,445.59
73 reported records · 15 companies
Healthcare provider profile · identity verified
Timothy J Hoffman, DO
Allopathic & Osteopathic Physicians|Internal Medicine · TOWANDA, PA · NPI 1417922394
Verified facts
What the public records show
CMS Open Payments records show Timothy J Hoffman, DO received $1,445.59 in general payments during 2025 across 73 reported records.
Novo Nordisk Inc accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 480 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $317.42 | 22.0% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $287.73 | 19.9% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $167.15 | 11.6% | 12 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $141.55 | 9.8% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $104.41 | 7.2% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $82.88 | 5.7% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $78.01 | 5.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.36 | 5.1% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $66.81 | 4.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.06 | 2.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $22.81 | 1.6% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.77 | 1.4% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $18.39 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.69 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.55 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,427.90 | 72 |
| Education | $17.69 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $317.42 | 19 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $242.13 | 15 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $206.57 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $164.00 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $152.78 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $141.55 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $113.35 | 8 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $104.41 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $82.88 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $78.01 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $66.81 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.41 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $53.80 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $53.80 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.06 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.06 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 480 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 82 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 203 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 95 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
104 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
203 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
95 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
480 | 59 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1104 | 252 |
| Furosemide | Furosemide | 857 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 834 | 180 |
| Atorvastatin Calcium | Atorvastatin Calcium | 820 | 168 |
| Pantoprazole Sodium | Pantoprazole Sodium | 698 | 164 |
| Tamsulosin Hcl | Tamsulosin Hcl | 590 | 128 |
| Gabapentin | Gabapentin | 558 | 116 |
| Lisinopril | Lisinopril | 542 | 125 |
| Omeprazole | Omeprazole | 505 | 127 |
| Metformin Hcl | Metformin Hcl | 486 | 116 |
| Eliquis | Apixaban | 480 | 59 |
| Citalopram Hbr | Citalopram Hydrobromide | 473 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 458 | 121 |
| Simvastatin | Simvastatin | 435 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 396 | 118 |
| Sertraline Hcl | Sertraline Hcl | 388 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 378 | 66 |
| Quetiapine Fumarate | Quetiapine Fumarate | 368 | 56 |
| Losartan Potassium | Losartan Potassium | 340 | 92 |
| Metoprolol Tartrate | Metoprolol Tartrate | 305 | 55 |
| Valsartan | Valsartan | 301 | 78 |
| Donepezil Hcl | Donepezil Hcl | 278 | 51 |
| Azithromycin | Azithromycin | 276 | 203 |
| Allopurinol | Allopurinol | 267 | 50 |
| Montelukast Sodium | Montelukast Sodium | 265 | 71 |
| Spironolactone | Spironolactone | 254 | 51 |
| Finasteride | Finasteride | 243 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 74 |
| Tramadol Hcl | Tramadol Hcl | 236 | 67 |
| Prednisone | Prednisone | 223 | 78 |
| Glimepiride | Glimepiride | 219 | 59 |
| Carvedilol | Carvedilol | 213 | 30 |
| Jardiance | Empagliflozin | 203 | 44 |
| Meloxicam | Meloxicam | 195 | 45 |
| Xarelto | Rivaroxaban | 182 | 35 |
| Buspirone Hcl | Buspirone Hcl | 173 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 36 |
| Levetiracetam | Levetiracetam | 156 | 17 |
| Alprazolam | Alprazolam | 149 | 46 |
| Potassium Chloride | Potassium Chloride | 148 | 44 |
| Atenolol | Atenolol | 146 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 137 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 44 |
| Trazodone Hcl | Trazodone Hcl | 136 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 135 | 32 |
| Aripiprazole | Aripiprazole | 128 | 16 |
| Warfarin Sodium | Warfarin Sodium | 128 | 18 |
| Mirtazapine | Mirtazapine | 124 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 59 |
| Lorazepam | Lorazepam | 119 | 42 |
| Methylprednisolone | Methylprednisolone | 118 | 100 |
| Paroxetine Hcl | Paroxetine Hcl | 116 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 112 | 78 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 109 | 16 |
| Olanzapine | Olanzapine | 107 | 16 |
| Januvia | Sitagliptin Phosphate | 105 | 13 |
| Synthroid | Levothyroxine Sodium | 104 | 32 |
| Fenofibrate | Fenofibrate | 102 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 21 |
| Famotidine | Famotidine | 100 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 99 | 18 |
| Cinacalcet Hcl | Cinacalcet Hcl | 99 | suppressed |
| Glipizide | Glipizide | 96 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 19 |
| Rexulti | Brexpiprazole | 95 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 91 | 18 |
| Clonazepam | Clonazepam | 89 | 20 |
| Levofloxacin | Levofloxacin | 89 | 57 |
| Ozempic | Semaglutide | 89 | 27 |
| Cephalexin | Cephalexin | 86 | 63 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 58 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 20 |
| Celecoxib | Celecoxib | 82 | 22 |
| Farxiga | Dapagliflozin Propanediol | 82 | 14 |
| Primidone | Primidone | 82 | suppressed |
| Torsemide | Torsemide | 81 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 79 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 23 |
| Memantine Hcl | Memantine Hcl | 72 | 12 |
| Ramipril | Ramipril | 71 | 20 |
| Fluconazole | Fluconazole | 70 | 46 |
| Mounjaro | Tirzepatide | 70 | 16 |
| Metolazone | Metolazone | 69 | 16 |
| Risperidone | Risperidone | 68 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 67 | suppressed |
| Nifedipine Er | Nifedipine | 64 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 22 |
| Labetalol Hcl | Labetalol Hcl | 61 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 23 |
| Sucralfate | Sucralfate | 60 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 59 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 59 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 41 |
| Cilostazol | Cilostazol | 58 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 56 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 56 | 11 |
| Temazepam | Temazepam | 56 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 15 |
| Loperamide | Loperamide Hcl | 53 | 24 |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | suppressed |
| Ezetimibe | Ezetimibe | 52 | 22 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 51 | 13 |
| Entresto | Sacubitril/Valsartan | 51 | 11 |
| Methocarbamol | Methocarbamol | 51 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 51 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 26 |
| Bumetanide | Bumetanide | 45 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 12 |
| Pregabalin | Pregabalin | 44 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 43 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 42 | suppressed |
| Digoxin | Digoxin | 42 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 42 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 12 |
| Eszopiclone | Eszopiclone | 40 | 12 |
| Meclizine Hcl | Meclizine Hcl | 40 | 21 |
| Nystatin | Nystatin | 40 | 21 |
| Propranolol Hcl Er | Propranolol Hcl | 40 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 11 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Latanoprost | Latanoprost | 37 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 36 | suppressed |
| Colchicine | Colchicine | 35 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 32 | 23 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 31 | 31 |
| Cholestyramine | Cholestyramine (With Sugar) | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 19 |
| Terbinafine Hcl | Terbinafine Hcl | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Fentanyl | Fentanyl | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 22 |
| Trospium Chloride | Trospium Chloride | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Armour Thyroid | Thyroid,pork | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | 12 |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 14 |
| Epinephrine | Epinephrine | 21 | 11 |
| Ramelteon | Ramelteon | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Scopolamine | Scopolamine | 20 | suppressed |
| Imiquimod | Imiquimod | 19 | 12 |
| Letrozole | Letrozole | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | 14 |
| Nateglinide | Nateglinide | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 16 | 11 |
| Budesonide Ec | Budesonide | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 11 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,445.59 · 73 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, ELIQUIS, EVENITY, FARXIGA, JARDIANCE, Leqembi, MOUNJARO, NEFFY, NURTEC ODT, Ohtuvayre, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error